å»è¬åå ¬è¡šãããæŽå¯
äžçèŠæš¡ã®ãã©ããªãŒãžã£50åžå Žãè©äŸ¡ãããŸãã US$ 130.3 Mn ã§ 2025 ãããŠå°éããäºå® US$ 263.7 ãã ã«ãã£ãŠ Mn 2032, ååç©å¹Žéæé·çã§æé· 2025幎ãã2032幎ã«ãããŠ10.6%ã®CAGRãã°ããŒãã«ã»ã¹ãã¹ãã£ãã¯ã»ãã©ããªãŒãžã£50åžå Ž-å°åçæŽå¯åã¢ã¡ãªã« äºæž¬æéäžã50ã®åžå ŽèŠæš¡ã§æå€§èŠæš¡ã®åžå Žã§ããããšãæåŸ ããã2025 North Americaã®åžå Žã·ã§ã¢ã®35.7%以äžãå ãããã°ããŒãã«ã»ã¹ãããã¯ã»ãã©ããªãŒãžã£50åžå Žã«ãããåªäœæ§å°åãšããŠã®å°äœã確ç«ããŸããã äž»èŠãªè£œè¬äŒç€Ÿã®ååšãšç¢ºç«ãããå»çã€ã³ãã©ã¯åžå Žæ... ãã£ãšèŠã
ã°ããŒãã«ã¢ã¹ãªãŒãã®è¶³åžå Žãè©äŸ¡ãããŸãã US$ 1.41 ãã³ã ãåãåãã 2025幎 ãããŠå°éããäºå® US$ 1.99 ãã³ ã«ãã£ãŠ 2032幎, ååç©å¹Žéæé·çã§æé· (CAGR) ã® 5.0%(çšæ) 2025幎ïœ2032幎Athleteã®è¶³ã¯ãããããã£ã¹ãšãåŒã°ããè¶³ã®ã€ãŸå ãšãœãŒã«ã®éã«ç®èã«åœ±é¿ãäžããç®èç§ã«ãã£ãŠåŒãèµ·ããããè¶³ã®äžè¬çãªçèææçã§ãã å¥åº·æèãé«ããã¹ããŒããéåæŽ»åãžã®åå ãå¢å ãããã¢ã¹ãªãŒãã®è¶³ãã°ããŒãã«ã«å¹æçã«æ²»çããäºé²ããããã®éèŠãé転ããŠããŸãã å»ççæ³ã®é²æ©ãšæ°ãããããã¯ãšçµå£ã®å°å ¥ æçèè¬ æ¹åãããå¹åã«... ãã£ãšèŠã
äžççãªæ¥æ§ãžã¹ããã¢åžå Žãè©äŸ¡ãããŸãã US$ 120.8 Mn ã§ 2025 ãããŠå°éããäºå® US$ 152.6 Mn ã«ãã 2032 æé·ãã 3.4%ã®ååç©å¹Žéæé·ç(CAGR) 2025幎ïœ2032幎Anticholinergicã®è¬ç©ãtrihexyphenidylããã³benzatropineã®ãããªãããã£ã®ååŠã¡ãã»ã³ãžã£ãŒã劚ããããšã«ãã£ãŠåããŸãã ããã¯ããžã¹ããã¢ã«ãã£ãŠåŒãèµ·ããããçèã®çæ£ãæžããã®ã«åœ¹ç«ã¡ãŸãã ããããæã³ãªã³è¬ã¯ãæ¯ç©Žã®ãããªå¯äœçšãåŒãèµ·ããå¯èœæ§ããããŸã ããžã§ã³ã䟿ç§ããã³ä¹Ÿç¥ããå£ã çŠæç¥çµäŒéç©è³ªãGABAã®å¹æã... ãã£ãšèŠã
ã°ããŒãã«ã»ãã©ã³ã«ã¡ã·ã³åžå Žãè©äŸ¡ããã US$ 822.9 Mn ã« 2025ãããŠå°éããäºå® US$ 1,082.8 Mn ã«ãã 2032ãæ··åç©ã®å¹Žæ¬¡æé·ç(CAGR)ã®å±ç€º 4.0%ã® ãã 2025幎ïœ2032幎Blarcamesine(å¥åANAVEX2-73)ã¯Sigma-1åå®¹äœæŽ»æ§å€ãšåŒã°ããè¬ã®ã¯ã©ã¹ã«å±ããŸãã ã·ã°ã-1å容äœã¯ã掻æ§åããããšãã现èå ã®é žå鲿¢ããã³ç¥çµä¿è·ããã»ã¹ãä¿é²ããåèšåºæ€æ»ã¢ãã«ã§ã¯ããã©ãŒã«ã¡ã·ã³ã¯ããã®è¬ã®èšåºæ€æ»ã«ã€ãªããã®ããŒãã³ãœã³ã®æå©ã¢ãã«ã«ç€ºãããŠããŸããã°ããŒãã«Blarcamesineåžå Ž - å°åæŽå¯åã¢ã¡ãªã«... ãã£ãšèŠã
Zambia cholera ã¯ã¯ãã³åžå Žãè©äŸ¡ãããŸãã US$ 1.5 Mn ã§ 2025 ãããŠå°éããäºå® US$ 3.8 Mn ã«ãã 2032 å±ç€ºäŒåºå±ã®ãæ¡å ååç©å¹Žéæé·ç(CAGR)14.4% 2025幎ïœ2032幎Choleraã¯ãé£ç©ãæ°ŽãéããŠäžè¬çã«åºãã现èã®ç æ°ã§ãã ããã¯é床ã®äžç¢ããã³è±æ°ŽãåŒãèµ·ãããŸãã 人ã ã¯ãäºé²æ¥çš®ãåããããšã«ãã£ãŠãã³ã¬ã¹ãããŒã«ã«å¯ŸããŠä¿è·ãããå ç«åããããšãã§ããŸãã ãããã®ã¯ã¯ãã³ã®2çš®é¡ããããŸãããªãŒã©ã«O1ãšå šã»ã«BãµããŠããããã«ããšãªãŒã©ã«O1&O139ãã«ãã 2幎以äžã®å ç«ã®ããã«ããã®æ®ºãããã¯ã¯ã... ãã£ãšèŠã
ã°ããŒãã«ãªãŒãçå矀治çåžå ŽèŠæš¡ã¯ã 2025幎ã®US $ 273.3çŸäžãããŠå°éããäºå® US$ 436.0 çŸäž 以 2032, æé· ååç©å¹Žéæé·ç(CAGR) 6.9% ãã 2025幎ïœ2032幎Leigh Syndrome æ²»çåžå Ž å°å æŽå¯åã¢ã¡ãªã« æ¥çãªãŒããŒã®åŒ·ãååšãšæ£è ã®æèãé«ããããã«æ°å¹ŽéãäžççãªãªãŒã°çå矀治çåžå Žãæ¯é ããŠããŸãã ç±³åœã¯ãããã補è¬äŒç€Ÿããžã§ããªãã¯ã¡ãŒã«ãŒã®éäžã«ããå°åã«ãããåžå Žã·ã§ã¢ã®å€§åãå ããŠããŸãã ããã«ãå é²å»çæœèšã®æ¯æŽã«ããé«èšºæçãããã«ã¹ã±ã¢æ¯åºã®äžæãªã©ã«ãããå°åã¯é åçãªåžå Žã§ãã ããããç é¢ãä¿éº... ãã£ãšèŠã
äžçã®æ¿ããåã®åŠçœ®ã®åžå Žã¯ã§è©äŸ¡ãããŸãã US$ 2.08 ã§ 2025 ãããŠå°éããäºå® US$ 2.85 ã〠2032, ååç©å¹Žéæé·çã§æé· (CAGR) ã® 4.6% 2025幎ïœ2032幎ã°ã«ãŒãA Streptococcal(GAS)ã®åœé çãšãåŒã°ããã¹ãã¬ãåã¯ãã¹ãã¬ããã³ãã«ã¹pyogenes现èã«ãã£ãŠåŒãèµ·ããããåãšææ¡ã®çŽ°èææã§ãã å·ŠãæªåŠçã®å Žåãæ·±å»ãªå䜵çã«ã€ãªããå¯èœæ§ããããŸãã strep ã®åã®ããã«å©çšã§ããè€æ°ã®åŠçœ®ã®éžæããããŸãã æãäžè¬çãªã®ã¯ãçµå£æäžãäŒŽã æçç©è³ª ããã·ãªã³ãã¢ã¢ãã·ã·ãªã³ã®ãããªã ãããã®æçç©è³ªã¯... ãã£ãšèŠã
ã°ããŒãã«myomectomyåžå ŽèŠæš¡ãæåŸ ããã US$ 1,486.7 ã«ãã£ãŠ 2032, US$ 792.7 2025幎ã®Mnã9.4%ã®ååç©å¹Žéæé·ç(CAGR)ãå±ç€º äºå ±æéäž(2025-2032).Myomectomyã¯ãåå®®å ãŸãã¯å¥³æ§ã®åå®®ã«çºéããéå€èæé·ã§ããç·ç¶çãé€å»ããããã«è¡ãããå€ç§çåŠçœ®ã§ãã ããã€ãã®æ°ããµã€ãºãå Žæã«å¿ããŠå®è¡ã§ããããŸããŸãªçš®é¡ã®myomectomiesããããŸããã°ããŒãã«Myomectomyåžå Ž - å°åæŽå¯åã¢ã¡ãªã« 2025幎ã®åžå Žã·ã§ã¢ã®41.4%以äžãå ããäºæž¬æéäžãmyomectomyã®æå€§ã®åžå Žã§ããããšãæåŸ ã... ãã£ãšèŠã
ã°ããŒãã«éºäŒæ§ãªããã£ãã¯é žå°¿è¬åžå Žãè©äŸ¡ãããŸãã US$ 358.2 Mn ã§ 2025 ãããŠå°éããäºå® US$ 494.1 Mn ã«ãã 2032, å±ç€ºäŒ 2025幎ãã2032幎ãŸã§ã®4.7%ã®ååç©å¹Žéæé·ç(CAGR)ãéºäŒæ§ãªãã¯é žå°¿çŽ ã¯ãuracil-5'-phosphateãã«ã«ããã·ã©ãŒãŒãšããŠç¥ãããé µçŽ ã®æ¬ ä¹ã«ãããŸãã§ãèªåŸçãªéå éºäŒåé害ã§ãã ãã®é µçŽ ã¯ããªããã£ãã¯é žã®åè§£ã®ããã«äžå¯æ¬ ã§ãããããã«ãã£ãŠå°¿äžã®èç©ãšçµæ¶åã«ã€ãªãããæ¬ ä¹çãçºçããå Žåã éºäŒæ§ãªããã« - ã¿ã€ãIãšã¿ã€ãIIã®2ã€ã®äž»èŠãªã¿ã€ãããããŸãã ã¿ã€ã: uraci... ãã£ãšèŠã
ã°ããŒãã«ãª cleft lip æè¡åžå Žã¯ã US$ 450.5 ã¡ãŒãã« ãåãåãã 2025幎 ãããŠå°éããäºå® US$651.0 Mn ã«ãã£ãŠ 2032å¹Žãæ··åã®å¹Žæ¬¡æé·çã§è²ã€ 2025ã2032幎(CAGR)å£è ãŸãã¯å£èã®ç¹å®ã®çµç¹ãèå ã®çºéäžã«å®å šã«çµåã§ããªãã£ããšããå·Šã¯èµ·ãããŸãã æ¡ä»¶ã¯ãå£çŽ ãã¬ã ãå£ã®å±æ ¹ãéã£ãŠã錻è ã«æ¡åŒµã§ããéå£éšãæ®ããŸãã å·Šã®æªåŠçãå·Šã®åããã³palatesã¯äŸçµŠãã¹ããŒããæ¯ç§å¥åº·ããã³ç€ŸäŒçãªstigmaã®å°é£ãåŒãèµ·ããããšãã§ããŸãã 幞ãã«ããå·Šã®åãšå£èã®æè¡ã¯ãéå»10幎éã§å€§å¹ ã«é²ãã§ããŸãã å€ç§çä¿®çãšãªãã... ãã£ãšèŠã
äžççãªçµå£æäžã«ã³ãžãçåžå Žã¯ã US$ 456.4 ã¡ãŒãã« ãåãåãã 2025幎 ãããŠå°éããäºå® US$ 612.8 ã¡ãŒãã« ã«ãã£ãŠ 2032å¹Žãæ··åç©ã®å¹Žæ¬¡æé·çã§å±ç€ºãã 2025幎ãã2032幎ãŸã§ã®4.3%ã®CAGRãåãåããçµå£ã¹ã©ãã·ã¥ãšããŠäžè¬çã«ç¥ãããŠããçµå£ã«ã³ãžãçã¯ãå£è å ã«ã³ãžãã¢ã«ãã«ã³ãªã©ã®ã«ã³ãžãçèçš®ã«ãã£ãŠåŒãèµ·ããããçèææçãæããŸãã ããã¯å ç«æåãšå ç«æåã®äž¡æ¹ã®å人ã«åœ±é¿ãäžããæãäžè¬çãªäžåè¡¡çèææçã®äžã€ã§ãã ããå ç«æ¬ ä¹çãŠã€ã«ã¹/å ç«æ¬ ä¹ççå矀(HIV/AIDS)ãç³å°¿ç ãããæ²»çãã³ã«ãã³ã¹ããã€ããŸãã¯æ... ãã£ãšèŠã
äžççãªNPHP5ã®retinalã®åçã®åŠçœ®ã®åžå Žã®ãµã€ãºã¯éããããšãæåŸ ãããŸã US$ 133.3 ãã 2032 ãŸã§ US$ 15.8 2025幎ã®Mnã35.6%ã®ååç©å¹Žéæé·ç(CAGR)ãå±ç€º äºå ±æéäžãNPHP5ã®ç¶²èã®åçã¯ãé²è¡æ§ããžã§ã³ã®æå€±ãåŒãèµ·ãããŸãã§ãç¶æ¿ãããç¶²èçã§ãã NPHP5éºäŒåã®å€ç°ã«ãã£ãŠåŒãèµ·ããããçŒã®å å容äœã·ãªã¢ã®æ§é ãšæ©èœãç¶æããã®ã«åœ¹ç«ã¡ãŸããã°ããŒãã«NPHP5ã¬ããã«ã»ããžã§ãã¬ãŒã·ã§ã³ã»ããªãŒãã¡ã³ãã»ããŒã±ããåã¢ã¡ãªã« NPHP5ã®æå€§ã®åžå Žã§ããããšãæåŸ ãããŠããŸã ã¬ãã£ãã« 2025幎ã®åžå Žã·ã§ã¢ã®43.7... ãã£ãšèŠã
äžçã®ãããããããã³å¿æž©è£œååžå ŽèŠæš¡ã¯è©äŸ¡ããããšæšå®ãããŸã US$ 3.91 Bn ã§ 2025 ãããŠå°éããäºå® US$ 7.01 ã«ãã£ãŠ 2032, å±ç€º ååç©å¹Žéæé·ç(CAGR) 8.7% ãã 2025幎ïœ2032幎ã°ããŒãã«ããªãŒããã£ãã¯ãããŒã¢ã¯ãŒã 補ååžå Ž å°åçæŽå¯åã¢ã¡ãªã« äžçã®åçã®44.6%以äžãå ããäžççãªããªãŒããããããã³å¿æž©è£œååžå Žãæ¯é ããŸãã 倧å£åžå Žã·ã§ã¢ã¯ããããã®ææç©ãããããã«ã¹ã±ã¢è£œåã«å¯Ÿããæèã®å¢å ãå°åã«ãããäž»èŠãªæ¥çã®éžæã®ååšãªã©ã®èŠå ã«ãããã®ã§ãã ã¢ã¡ãªã« ããã ææè ã¯ããããã®å¹žçŠã確ä¿ãããããã±ã¢ã«ãŒ... ãã£ãšèŠã
äžççãªã¢ã·ã³ããã¯ã¿ãŒèºçã®æ²»çè¬åžå ŽèŠæš¡ã¯å°éãããšäºæ³ãããŸã US$ 1,076.0 ãã 2032, US$ 725.1 2025幎ã®Mnã¯ã5.8%ã®CAGRãå±ç€ºããŸã äºå ±æéäžãAcinetobacter pneumoniaã¯ãAcinetobacter bacteriumã«ãã£ãŠåŒãèµ·ããããäžéåŸ³ãªææçã§ãã ãããã®çްèã¯ãããŸããŸãªãã«ã¹ã±ã¢é¢é£ã®ææçãåŒãèµ·ããå¯èœæ§ããããäžççã«éèŠãªç åäœãšããŠæ°èããŠããŸãã çŸåšãAcinetobacter pneumoniaãæ²»çããããã®æ²»çãªãã·ã§ã³ãéãããŠããŸããã°ããŒãã«ã¢ã·ã³ããã¯ã¿ãŒèºçæ²»çåžå Ž-å°åæŽ... ãã£ãšèŠã
äžçã®ã¹ãã³ ã±ã¢ã®è£è¶³ã®åžå Žã®ãµã€ãºã¯è©äŸ¡ãããŸãã US$ 15.21 ãã 2025幎ã®Bn ãããŠæåŸ ããã ãªãŒã US$ 26.57 ã«ãã£ãŠ 2032, æé· ååç©å¹Žéæé·ç(CAGR) 8.3% 2025幎ïœ2032幎ã¹ãã³ã±ã¢ãµããªã¡ã³ã ããŒã±ããã»ãªãŒãžã§ãã«ã»ã€ã³ãµã€ãåç±³ã¯ãã°ããŒãã«ã§åªå¢ãªå°åãšããŠç¢ºç«ããŸãã ã¹ãã³ 40.8%ã®ã±ã¢ãµããªã¡ã³ãåžå Žã ç±³åœãç¹ã«ãæ¶è²»è ãšé«ãäœ¿ãæšãŠæåŸã¬ãã«ã®å¥åº·æèãé«ãããããæå€§ã®åžå Žã·ã§ã¢ã®ã¢ã«ãŠã³ãã ç³å°¿ç ã®ã¹ã±ãžã¥ãŒã«ãšçžãŸã£ãŠããŸããŸã座ã£ãã©ã€ãã¹ã¿ã€ã«ã¯ãæ¯æ¥ã®ã¹ãã³ã±ã¢ã®ã«ãŒãã³ãè£å®ã§ããæ é€è£å©é£... ãã£ãšèŠã
äžçã®ã¢ããªçå矀(MPS-IV)å»è¬ååžå ŽèŠæš¡ãæåŸ ããã 2025幎 US$ 1.9 Mn ãã 2032 幎ãŸã§ã® US$ 4.4 Mn ã§ãååç©ã®å¹Žéæé·ç (CAGR) ã 12.7% ã«å±ç€º äºå ±æéäžãã ã³ããªç³è³ªçã¿ã€ãIV(MPS IV)ãšãåŒã°ããã¢ããªçå矀ã¯ãé害ã®ããéçºãšçã身é·ãç¹åŸŽãšãããŸããªéºäŒç ã§ãã ããã¯ã°ãªã³ãµããã°ãªã«ã³ã®åè§£ã®ããã«èŠæ±ãããé µçŽ N-acetylgalactosamine-6ã¹ã«ãã¡ã¿ãŒãŒã®æ¬ ä¹ã«ãã£ãŠåŒãèµ·ããããã MPS IVã®çŸåšã®æ²»çãªãã·ã§ã³ã¯ãçç¶ç®¡çãšãµããŒãã«éãããŸã æ¡çšæ å ±ãåãåããäžçã®Morquioã·... ãã£ãšèŠã
äžççãªãã£ãã«ç ã®æ²»çè¬åžå ŽèŠæš¡ã¯å°éãããšäºæ³ãããŸã US$ 160.2 Mn ãã 2032 US$ 145.3 2025幎ã®Mnã1.4%ã®ååç©å¹Žéæé·ç(CAGR)ãå±ç€º äºå ±æéäžãç ç©¶éçº(ç ç©¶éçº)ã¯ãæ²»çã®ããã®èšåãæäŸããéå®³ã®æ²»çã®ããã®èŠæ±ã®å¢å ãåžå Žã®æé·ãé«ããããã«æåŸ ããããã€ãªãã¯ãããžãŒããã³è£œè¬äŒç€Ÿã«ããæŽ»åãã°ããŒãã«ãã£ãã«ç ã®æ²»çè¬åžå Ž - å°åæŽå¯åã¢ã¡ãªã« 2025幎ã®åžå Žã·ã§ã¢ã®43.7%以äžãå ãããäºæž¬æéäžã«ãã£ãã«ç æ²»çåžå Žã®ããã®æå€§ã®åžå Žã§ããããšãæåŸ ãããŸãã åã¢ã¡ãªã«å°åã¯ãè€æ°ã®ããã補è¬äŒç€Ÿãšå€§èŠæš¡ãªå»çè²»ã®ååšã§... ãã£ãšèŠã
äžççãªã¢ã©ã³ã»ãã«ã³ãã³ã»ãã¬ãŒçå矀(AHDS)(MCT8æ¬ ä¹)åžå ŽèŠæš¡ãæåŸ ããã US$ 20.8 ã«ãã£ãŠ 2032, US$ 14.1 ãã 2025幎ã®Mnã¯ã5.7%ã®æ··åç©ã®å¹Žæ¬¡æé·ç(CAGR)ãå±ç€ºããŸã äºå ±æéäžãAllan-Herndon-Dudleyçå矀(AHDS)ã¯ãMCT8éºäŒåã®å€ç°ã«ãã£ãŠåŒãèµ·ãããããŸããªéºäŒçé害ã§ãã ãããã®å€ç°ã¯ãè¡è³ã®éå£ãæž¡ãç²ç¶è ºãã«ã¢ã³ã®èŒžéãæãªãçµæããããããŸãã AHDSã®çŸåšã®æ²»çæ³ã®éžæè¢ã¯éãããŠãããçç¶ã®ç®¡çãç®æããŠããŸãã æ²»çã®æåã®ã©ã€ã³ã¯ç²ç¶è ºãå«ã¿ãŸã ãã«ã¢ã³è£å çæ³ Triiodoth... ãã£ãšèŠã